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Abstract
Tumor-associated neoangiogenesis and suppression of antitumor immunity are hallmarks of tumor development
and progression. Death receptor 6 (DR6) has been reported to be associated with suppression of antitumor immunity
and tumor progression in several malignancies. However, expression of DR6 bymalignant ovarian epithelial tumors at
an early stage is unknown. The goals of this study were to determine whether DR6 is expressed by malignant ovarian
epithelial tumors at an early stage and to examine whether DR6 expression is associated with ovarian cancer (OVCA)
progression in a laying hen model of spontaneous OVCA. Expression of DR6 was examined in normal and malignant
ovaries, normal ovarian surface epithelial (OSE) cells, or malignant epithelial cells and in serum of 3-year-old hens. The
population of microvessels expressing DR6 was significantly higher in hens with early-stage OVCA than hens with
normal ovaries (P < .01) and increased further in late-stage OVCA. The results of this study showed that, in addition
to microvessels, tumor cells in the ovary also express DR6 with a significantly higher intensity than normal OSE cells.
Similar patterns of DR6 expression were also observed by immunoblot analysis and gene expression studies. Fur-
thermore, DR6 was also detected in the serum of hens. In conclusion, DR6 expression is associated with OVCA
development and progression in laying hens. This study may be helpful to examine the feasibility of DR6 as a useful
surrogatemarker ofOVCA, a target for antitumor immunotherapy andmolecular imaging and thusprovide a foundation
for clinical studies.
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Introduction
Ovarian cancer (OVCA) is the most lethal tumor among gynecologic
malignancies, with an estimated yearly incidence rates of 22,000 in the
United States and 42,000 in Europe [1,2]. In most cases, OVCA is
detected at advanced stages, and despite the remarkable improvements
in treatment strategies, most of these patients have recurrences. The
reasons for failure to detect and treat OVCA at an early stage as well
as its high rate of recurrences are the lack of an effective early detection
test, suppression of antitumor immunity by the tumor, and resistance
to drugs [3–5]. OVCA differs from other malignancies in its specific
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dissemination pattern, which is characterized by tumor spread in a
diffuse intrapelvic and abdominal manner [5]. Thus, the local tumor
microenvironment including tumor-associated neoangiogenesis and
suppression of antitumor immunity play important roles in the devel-
opment and progression of ovarian tumors. However, the way tumor
establishes neoangiogenesis and escapes antitumor immune surveillance
is not well understood. Information on factors related to the develop-
ment of tumor-associated angiogenesis and immune suppression in the
tumor microenvironment is important because it may offer opportu-
nities to establish an early detection test as well as targeted antitumor
therapy. Death receptor 6 (DR6) has been suggested to be one of such
factors because of its expression by blood vessels and its involvement
in immunoregulation [6,7].
DR6 is a member of the tumor necrosis factor α receptor super-
family (TNFRSF21) [8,9]. Although DR6 has been shown to be in-
volved in apoptotic cell death, elevated expression of DR6 has been
observed in several tumors in humans [10]. DR6 expression was
increased in tumor tissues from patients with late-stage prostate and
breast cancers compared with its level in normal tissues [10]. Recently,
DR6 concentration in the serum has been shown to be elevated in
patients with late-stage OVCA [6]. In addition, DR6 has been dem-
onstrated to be expressed by blood vessels in tumor tissues [11]. All
these reports suggest that increased DR6 expression is associated
with advanced stages of several malignancies including OVCA. How-
ever, its association with early-stage OVCA including tumor-associated
angiogenesis is not known.
Suppression of antitumor immunity has been suggested as one of
the mechanisms of tumor survival and progression [5]. Despite the
presentation of antigens by malignant cells, which should induce
immune-mediated rejection, spontaneous rejection of established tumor
is rare [5]. Inefficient tumor rejection by the immune system is not
only a passive result of insufficient effector cells [12,13] because
tumors induce immune-suppressive mechanisms that protect them
against eradication [3,4]. Compared with other solid tumors, stud-
ies on immunosuppression by ovarian tumors are very few. As in
other epithelial malignancies, antitumor immune responses were
reported to be elicited against ovarian tumors [14–16], but these re-
sponses were not effective enough to eliminate bulky tumor [5].
Moreover, the distinctive type of disease dissemination (peritoneal
spread and metastasis) makes OVCA unique compared to other solid
tumors. Although the precise mechanism(s) of inadequate or defec-
tive antitumor immune responses are not well understood, expression
or secretion of immunosuppressive factors by the tumor has been
suggested as a potential strategy for immune evasion. DR6 has been
reported to alter normal differentiation of monocyte to immature
dendritic cells rather than mature dendritic cells [17] and immature
dendritic cells have been demonstrated to induce tolerance [18]. Fur-
thermore, because of its inhibitory roles in T- and B-cell proliferation
and migration, DR6 has been proposed to be immunosuppressive
and may be involved in tumor cell survival and immune evasion [7].
However, expression of DR6 by ovarian tumors at early stages as well
as inhibition of antitumor immunity by DR6 in OVCA patients is
not known.
To develop and improve the efficacy of an antitumor immuno-
therapy, more insight into the interaction between ovarian cancer
(OVCA) and the immune system is needed. Information on DR6
expression by ovarian tumors may lead to the identification of addi-
tional targets, which may allow opportunities for developing new ther-
apeutic approaches to inhibit tumor progression. Studies on the
immune response against tumors or immune suppression by ovarian
tumors at early stages are lacking. Furthermore, if DR6 is expressed
by ovarian tumor–associated neoangiogenic microvessels, it may be a
useful target for the early detection of OVCA by Doppler ultrasound
imaging. The difficulty in identifying patients with OVCA at an early
stage and the limited access to tumor tissue are significant barriers to the
study and to the development of an effective immunotherapy against
OVCA. Laying hens are the only widely available and easily accessible
animals that develop OVCA spontaneously with high incidence rates
and remarkably similar histologic subtypes and tumor markers to
human OVCA [19–21]. In addition, avian DR6 has been reported
to be orthologous to human DR6 (70% homology) and is expressed
by the hen ovaries [22]. Thus, the objective of the present study was
to explore whether DR6 is expressed by ovarian tumors in hens and,
if so, whether its expression changes in association with the stage of
the tumors and histologic subtypes.
Materials and Methods
Animals
A flock of 3-year-old commercial strains of White Leghorn laying
hens (Gallus domesticus) was maintained under standard poultry hus-
bandry practices. Hens (n = 120) were selected based on their egg laying
rates (normal or low) and transvaginal ultrasound scanning as reported
previously [23]. The incidence of OVCA in hens of this age group is
approximately 15% to 20% and is associated with low or complete
cessation of egg laying [19,23]. All experimental procedures were per-
formed according to the institutional animal care and use committee–
approved protocol.
Tissue Collection and Processing
Serum samples. Blood was obtained from brachial veins of all hens
before euthanasia and centrifuged (1000g for 20 minutes), and serum
samples were stored at −80°C.
Ovarian morphology and histopathology. Ovarian pathology and
tumor staging were performed by gross and histologic examination as
reported previously [19]. Each normal and malignant ovary (tumor
bearing ovary) was divided into four portions for protein extraction,
total RNA collection, paraffin and frozen embedding for routine his-
tology, and immunohistochemical studies as reported previously [24].
Normal ovarian surface epithelial (OSE) cells or tumor cells (malignant
epithelial cells of the tumor) in hens with OVCA were collected as
reported earlier [25,26]. Samples were divided into three groups includ-
ing normal and early- and late-stage OVCA based on gross inspection
and microscopy as previously reported [19].
Preparation of Ovarian Specimen for Biochemical Analysis
Snap-frozen ovarian tissues as well as normal OSE cells and tumor
cells from hens with normal ovaries or hens with OVCA were homog-
enized with a Polytron homogenizer (Brinkman Instruments,Westbury,
NY) as reported previously [27], were centrifuged; the supernatant was
collected and the protein content of the extract was measured and stored
at −80°C.
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Immunohistochemistry
Rabbit polyclonal anti-chicken DR6 antibodies were used as primary
antibodies, and immunoreactions were determined using Vectastain
Elite ABC kit (Universal, RTU; Vector Laboratories, Inc, Burlingame,
CA). Normal or malignant ovaries (n = 15 hens each for normal, early,
and late stages) were selected randomly for immunohistochemical
study. The number of hens for each group for immunohistochemistry
was determined based on the power analysis to achieve significant dif-
ferences in different parameters among the normal or malignant
groups. Briefly, after deparaffinization, antigens on the sections were
unmasked by heat treatment, endogenous peroxidase in the sections
was inactivated, and nonspecific staining was blocked by incubating
with 0.3% hydrogen peroxide in methanol and normal horse serum,
respectively. Sections were then incubated for 2 hours with primary
antibodies (1:100 dilution) followed by 1 hour of incubation with sec-
ondary antibodies (Vectastain Elite ABC kit; Vector Laboratories). Im-
mune reaction products on the sections were visualized by incubating
with diaminobenzidine and hydrogen peroxide mixture (DAB Peroxi-
dase Substrate Kit, 3,3′-diaminobenzidine; Vector Laboratories). Sec-
tions were then counterstained with hematoxylin, dehydrated, and
covered. Control staining was carried out simultaneously in which
the first antibodies were omitted and normal serum was used. No
staining was found in these control slides.
Sections were then examined under a light microscope attached to
digital imaging software (MicroSuite version 5; Olympus Corporation,
Tokyo, Japan). The population of microvessels expressing DR6 as well
as the intensity of DR6 staining by the normal ovarian stroma or stroma
(around the tumor) in malignant ovaries was determined. Three sec-
tions per ovary and five regions of interest with the highest immuno-
reactivity (20,000 μm2 per region at an objective of ×40 and ocular
magnification of ×10) per section were selected. Using the software,
the intensity of the DR6 immunostaining in each region was measured
and recorded as pixel values in 20,000 μm2 of the section as reported
previously [28]. The mean of pixel values of these five regions in a sec-
tion was considered as the intensity of DR6 in a 20,000-μm2 area of
each section. The mean intensity of three sections was considered as
the DR6 staining intensity in a 20,000-μm2 area of each normal or
malignant ovary. The groupwise DR6 staining intensity (normal or
tumor groups) was expressed as mean ± SD in a 20,000-μm2 area of
ovaries in normal or malignant groups. Similarly, and using the same
software, the population of microvessels expressing DR6 in the section
was counted and reported as the frequency (mean ± SD) of DR6-
expressing microvessels in a 20,000-μm2 area of the stroma of normal
or malignant ovaries as reported previously [29].
One-dimensional Western Blot
Ovarian expression of DR6 was confirmed by immunoblot analysis
using homogenates of normal (n = 5) or malignant ovaries as well as
normal OSE cells or tumor cells. Twelve samples (four from each of
the serous, endometrioid, and mucinous samples) at early and late stages
ofOVCAwere selected for immunoblot analysis based on their immuno-
reactivity for DR6 in immunohistochemistry. Immunoreactions on the
membrane were visualized as a chemiluminescence product (Super Dura
West substrate; Pierce/Thermo Fisher, Rockford, IL), and the image was
captured using a Chemidoc XRS (Bio-Rad, Hercules, CA). Similarly, se-
rum samples from the same hens used for ovarian DR6 expression were
selected for immunoblot analysis to examine the presence of DR6 in
serum. Serum samples were filtered by acetonitrile and chloroform-
methanol precipitation before using for immunoblot analysis [27].
Reverse Transcription–Polymerase Chain Reaction
DR6 mRNA expression was assessed by semiquantitative reverse
transcription–polymerase chain reaction (RT-PCR) as reported previ-
ously [30]. For RT-PCR analyses, serum and tissue samples from 5 hens
with normal ovaries, from 12 hens with early stages of OVCA (4 for
each histologic subtype), and from 12 hens with late stages of OVCA
(4 for each histologic subtype) were selected based on their reactivity in
immunohistochemistry and immunoblot analysis. Hen-specific DR6
primers were designed by OligoPerfect Designer software (Invitrogen,
Carlsbad, CA) using the DR6 sequence from the National Center for
Biotechnology Information (accession no. A1980074) as reported earlier
[22]. The forward primer was 5′-GAT GGAGGACAC CAC GCC-3′
and the reverse primer was 5′-TCG GGG TTG AGG ATG TGC-3′.
β-Actin was used as the endogenous control, with a forward primer of
Figure 1. Gross morphology of normal and malignant ovaries in lay-
ing hens. (A) Fully functional normal ovary in a laying hen. Laying
hens ovulate and subsequently lay eggs once a day for 5 or 6 days
in a week in a continuous manner and then take a pause for 1 day
before laying resumes. Thus, the ovary in a fully functional laying hen
contains a set of multiple large and growing preovulatory follicles
arranged in a hierarchy of sizes (F1-F5). The largest follicle (F1) is
destined to ovulate soon and then the second largest follicle (F2)
becomes F1 and a small growing follicle is recruited from the ovarian
stroma to the hierarchy to maintain the laying rates. (B) Ovarian
tumor at an early stage in a hen showing solid tumor mass (arrows)
limited to the ovary. (C) Ovarian tumor at a late stage. The tumor
(Tu) appears like a cauliflower and has metastasized to other organs
with accompanied profuse ascites (*).
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TGCGTGACATCAAGGAGAAG and a reverse primer of ATGC-
CAGGGTACATTGTGGT. The expected base pair size for the DR6
amplicon was 384 bp and that for β-actin was 300 bp. PCR ampli-
cons were visualized in a 3% agarose gel (Pierce/Thermo Fisher) in
Tris-acetate-EDTA (TAE) buffer and stained with ethidium bromide.
The image was captured using a ChemiDoc XRS system (Bio-Rad).
Statistical Analysis
The differences in the intensity of DR6 immunostaining and the
number of microvessels expressing DR6 in normal ovaries and malig-
nant ovaries were assessed by analysis of variance, F tests, and the
alternative nonparametric Kruskal-Wallis tests. Subsequently, pairwise
comparison between the groups (normal and early- and late-stage
OVCAs) by two-sample t tests and alternative Mann-Whitney tests
were performed. All reported P values are two-sided, and P < .05
was considered significant. Statistical analyses were performed with
SPSS (PASW) version 18 software (IBM, Inc, Armonk, NY).
Results
Ovarian Morphology
In laying hens, only the left ovary becomes functional, and the rate
of egg production declines with aging. A fully functional ovary contains
five to six developing large preovulatory follicles (Figure 1A). As the
hen ages, the rate of egg production decreases. The ovary of an older
(>3 years old) healthy hen with a low rate of egg production contains
fewer than three large preovulatory follicles. In apparently healthy hens
that have stopped laying eggs, the ovaries were atrophied and the
oviducts were smaller. Solid tissue masses either limited to a small part
or the entire ovary, with or without ascites, were observed in 12 hens.
These hens were diagnosed with early-stage OVCA (Figure 1B). In
16 hens, tumor had metastasized to the abdominal organs with mod-
erate to profuse ascites. These hens were diagnosed with late-stage
OVCA (Figure 1C).
Histopathology. Cortical follicles with or without distinguishable
granulosa cell and theca layer were embedded in the ovarian stroma
of hens with normal ovaries (Figure 2A). Tumors were confirmed in
all hens displaying gross ovarian solid masses (12 hens at early stage with
solid masses limited to the ovaries or in 16 hens with late-stage OVCA)
by routine histology (Figure 2, B-D). However, tumor-related micro-
scopic changes (including focal lesions containing large cells with irregu-
lar shapes and pleomorphic nuclei) were also found during histologic
examinations in 11 additional hens that had no gross ovarian tumor
and were grouped in early-stage OVCA. Thus, a total of 23 (12 +
11) hens had early-stage OVCA, 16 had late-stage OVCA, whereas
81 hens had normal ovaries. Tumors were typed as serous (n = 17),
endometrioid (n = 12), mucinous (n = 8), clear cell (n = 1), as well as
mixed (n = 1, seromucinous) as reported previously [19].
Tissue Expression of DR6
Microvessels expressing DR6 were detected in both normal and
malignant ovaries (Figure 3). Most of the DR6-expressing ovarian
Figure 2.Microscopic features of hen ovaries. Paraffin-embedded sections from normal or malignant ovaries with tumors were stained
with hematoxylin and eosin. (A) Section of a normal ovary showing a developing follicle embedded in the ovarian stroma. (B) Section of
an ovarian serous carcinoma showing a solid sheet of tumor surrounded by fibromuscular tissue. The tumor contains a labyrinth of
slitlike glandular spaces lined by cells with large pleomorphic nuclei and mitotic figures. (C) Section showing endometrioid carcinoma
displaying confluent back-to-back glands. Glands contain a single layer of epithelial cells with sharp luminal margins. (D) Section of a
mucinous carcinoma. Glands in clusters with scarce intervening stroma lined by columnar and goblet cells with intracytoplasmic mucin.
Original magnification, ×40.
Translational Oncology Vol. 5, No. 4, 2012 DR6 Expression in Ovarian Tumors Barua et al. 263
microvessels in hens with normal ovaries had thick, complete, and
continuous vessel walls with intense staining. These vessels were
located in the theca layer of the follicles and a few vessels were in the
ovarian stroma. In contrast, most of the DR6-expressing vessels in
malignant ovaries were discontinuous or incomplete with thin vessel
walls (Figure 3A). The number of DR6-expressing microvessels was
significantly higher (P < .01, exact Mann-Whitney test) in hens with
early (mean ± SD = 8.0 ± 2.29 microvessels per 20,000-μm2 area of
stroma) and late (13.0 ± 2.37 microvessels per 20,000-μm2 area of
stroma in malignant ovaries) stages of OVCA than in hens with normal
ovaries (3.0 ± 0.52 microvessels per 20,000-μm2 area of stroma
in normal ovaries; Figure 3B). However, significant differences in the
population of DR6-expressing microvessels among the histologic
subtypes were not observed.
Tumor cells (Figure 4A) as well as a few normal OSE cells expressed
DR6. In addition, rounded (T lymphocyte like) to irregularly shaped
(macrophage-like) DR6 cells were also detected in the stroma of the
normal ovaries or malignant ovaries. Compared with normal ovaries
(mean ± SD = 3.6 × 106 ± 3.8 × 105 in a 20,000-μm2 area), the inten-
sities of DR6 staining increased approximately 9-fold (P < .001) in hens
with early-stage OVCA and 13-fold (P < .001) in hens with late-stage
OVCA, respectively (Figure 4B). However, significant differences
in DR6 staining intensities were not observed among three different
histologic subtypes of OVCA in hens.
Figure 3. (A) Immunohistochemical detection of DR6-expressing microvessels in hen ovaries with or without tumor. (a) Section of a nor-
mal ovarian stroma immunostained by omitting primary antibodies used as control. No immunopositive vessel is seen. (b) Serial section
from the same normal ovary immunostained with primary antibodies. Very few DR6-expressing vessels are seen. (c) An ovarian section
from a hen with early-stage OVCA. Compared to the normal ovary, many DR6-expressing microvessels are seen in the stroma between
tumors. (d) Section of a malignant tumor from a hen with late-stage OVCA. Many DR6-expressing microvessels are localized in the
tumor stroma. BV indicates blood vessel; F, follicle; G, granulosa layer; T, theca layer; TS, tumor stroma. Arrows indicate DR6-expressing
microvessels. Original magnification, ×40. (B) Changes in the frequency of DR6-expressing ovarian microvessels relative to ovarian tumor
development and progression in hens. The frequency of microvessels expressing DR6 in a 20,000-μm2 area of normal (n = 15) and
malignant ovaries (expressed as the mean ± SD, n = 15 each for early and late stages). Compared to the normal ovary, the frequency
of microvessels expressing DR6 was significantly (P < .001) higher in hens with early-stage OVCA cancer and increased further (P < .001)
as the disease progressed to a late stage in hens. Each bar with a different letter indicates significant differences (P < .001) between
normal and tumor groups.
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Immunoblot analysis for DR6 protein in ovarian tissues and serum
samples. Immunohistochemical expression of DR6 in normal or
malignant ovaries was confirmed by immunoblot analysis using homoge-
nates of OSE cells (from normal ovaries) or tumor cells (from malig-
nant ovaries) as well as homogenates from whole normal or malignant
ovaries. A band of 50 to 60 kDa was detected in the homogenates
of cells (normal OSE cells or tumor cells) and tissues (whole normal
or tumor ovaries; Figure 5A). In addition, immunoreactive 50- to
60-kDa DR6 protein was also detected by immunoblot analysis in
the serum of hens with normal ovaries or those with OVCA
(Figure 5A). Compared with the whole ovarian homogenates or serum
from hens with normal ovaries, immunoreactivity for DR6 protein was
intense in the homogenates of malignant ovaries or serum from hens
with OVCA (Figure 5A). These results support the immunohisto-
chemical observation that OSE in hens with normal ovaries and tumor
cells in hens with OVCA express DR6 protein. Moreover, these epi-
thelial cells may be a source of DR6 proteins in the circulation of lay-
ing hens because DR6 was detected in the serum of hens with normal
ovaries or those with OVCA.
Expression of DR6 messenger RNA. DR6 messenger RNA
(mRNA) expression confirmed the observed variations in ovarian
DR6 expression among hens with normal ovaries or those with
OVCA. Although the patterns of DR6 mRNA expression were sim-
ilar between normal OSE and tumor cells from early-stage OVCA, it
was stronger for tumor cells from late-stage OVCA. Compared with
the hens with normal ovaries, strong amplification of signal for DR6
(Figure 5B) was observed in the ovarian extracts from hens with early-
stage OVCA and the amplification was stronger in hens with late-
stage OVCA. However, differences in DR6 mRNA expression were
Figure 4. (A) Expression of DR6 by tumor cells in malignant ovaries in hens. (a) Section of a normal ovary immunostained for DR6
expression. Very few immunopositive cells are present in the ovarian stroma. (b-d) Sections of different histologic subtypes of OVCA
in hens including serous (b), endometrioid (c), and mucinous (d) at early stages immunostained for DR6 expression. Compared with the
normal OSE cells, tumor cells in all three histologic subtypes stained intensely. Original magnification, ×40. (B) Changes in the DR6
staining intensity relative to ovarian tumor development and progression in hens. The intensity of DR6 staining is expressed as the pixel
values (mean ± SD) in a 20,000-μm2 area in normal ovarian stroma (n = 15) or in malignant ovaries. Compared to the normal ovary, the
intensity of DR6 staining was significantly (P < .001) higher in hens with early-stage OVCA (n = 15) and increased further (P < .001) in
late-stage OVCA (n = 15). Each bar with different letter indicates significant differences (P < .001) among normal or OVCA stages.
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not observed among different histologic subtypes of OVCA at the
same stage (early or late). Overall, compared to hens with normal
ovaries, strong amplification of DR6 mRNA was observed in hens
with OVCA as observed for immunoreactivities in immunohisto-
chemistry and immunoblot analysis.
Discussion
This is the first report on the expression of death receptor (DR6) by
tumor cells of malignant ovaries in hens. The expression of DR6 was
significantly higher in the tumor cells of malignant ovaries than OSE
cells of normal ovaries. Furthermore, the population of ovarian micro-
vessels expressing DR6 was significantly higher in hens with early-stage
OVCA than hens with normal ovaries and increased further in hens
with late-stage OVCA. In addition, DR6 was also detected in the
serum of hens. Thus, the results of the present study suggest that
the increase in DR6 expression may be associated with ovarian tumor
development and progression in laying hens.
Tumor-associated neoangiogenesis (TAN) and suppression of anti-
tumor immunity are two of the early events required for the survival
and progression of the tumor. Increased numbers of immature micro-
vessels with disorganized and discontinuous smooth muscle layers
are the characteristic features of ovarian TAN in patients as well as
in laying hens with OVCA [24]. Compared to hens with normal
ovaries, the number of DR6-expressing microvessels was significantly
higher in hens with early-stage OVCA and increased further in hens
with late-stage OVCA. A recent study has reported increased expression
of DR6 by ovarian tumors in patients with advanced-stage OVCA [6].
In this study, the population of DR6-expressing ovarian microvessels
increased significantly at an earlier stage even before the tumor be-
came grossly detectable. Recently, DR6 was reported to be required
for angiogenesis in the central nervous system [31]. Although precise
reason(s) for the increase in the population of DR6-expressing micro-
vessels in malignant ovaries is not known, it is possible that DR6 will
play a role in the development of ovarian TAN.
Despite the presence of an antitumor immune response [5,32], the
rare eradication of ovarian tumors and their progression suggest that
multiple mechanisms are used by the tumor to escape immune rejection.
The expression of DR6 has been reported to be increased significantly
Figure 5. Immunoreactive (A) DR6 protein or (B) mRNA in serum and ovaries of hens with normal ovaries or those with OVCA. (A) One-
dimensional Western blot analysis: Immunoreactive DR6 proteins of 50- to 60-kDa molecular weight were detected in the homogenates
of normal OSE cells or tumor cells, in homogenates of whole normal or malignant ovaries, as well as in serum of hens by one-
dimensional Western blot. Compared to the hens with normal ovaries, relatively stronger immunoreactive bands for DR6 proteins were ob-
served in serum and ovaries of hens with early and late stages of OVCA. No immunoreactive band was detected in the negative control
in which protein sample was omitted. (B) Semiquantitative RT-PCR: mRNA expression for DR6 was detected in the extracts of normal
OSE cells or tumor cells and in extracts of normal and malignant ovaries by semiquantitative PCR. Compared to the weak expression by
normal ovaries and OSE, strong amplification for DR6 mRNA was observed in the extracts of malignant ovaries and tumor cells in hens
with early- and late-stage OVCA. No DR6 mRNA expression was detected in the negative control in which mRNA sample was omitted.
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in cell lines and patients with prostate and breast cancers [7,10,33]. In
the absence of DR6, ligation of the T-cell receptor results in enhanced
T-cell proliferation, activation, and skewed TH2 cytokine production.
Similarly, B cells lacking DR6 show increased proliferation, cell divi-
sion, and cell survival on mitogenic stimulation (anti-CD40 and LPS)
or BCR ligation. DR6−/− mice showed increased TH2 immune re-
sponses to both T-dependent and -independent antigens. In contrast,
it is suggested that increased DR6 expression on tumor cells results in
the cleaving of extracellular part of DR6 from the cell surface by matrix
metalloproteinase 14. This shed DR6 reported to attenuate the in vitro
differentiation of monocytes into immunotolerant instead of immuno-
competent dendritic cells, which can contribute to tumor evasion from
the immune system [17]. All these reports indicate that DR6 plays
important roles in imparting tolerance to local immune response. In
the present study, the expression of ovarian DR6 was significantly high
in hens with early-stage OVCA than in hens with normal ovaries and in-
creased further in hens with late-stage OVCA. Although the significance
of increased DR6 expression by malignant cells is not known, the results
of the current study suggest that increased DR6 expression may play
important roles in the suppression of immunity against ovarian tumors.
The results of the current study suggest several translational sig-
nificances. Because the malignant tumors in hens express DR6 and it is
also present in the serum, DR6 could be targeted for contrast-enhanced
ultrasound imaging to detect the tumor. Thus, use of DR6-expressing
epithelium in the ovary as a target may increase the sensitivity of ultra-
sound scanning to detect OVCA together with serum levels of DR6.
Hence, it will bring a significant change in imaging paradigms and
improve the specificity of ultrasound scanning. It will also make possible
to determine the time between the tumor-associated elevation of DR6
in serum and the earliest detection of tumor by contrast-enhanced ultra-
sound scanning. This information will enable the detection of OVCA at
an early stage and lead to the development of treatment modalities for
patients with OVCA. In addition, current findings will also be useful
in developing ovarian tumor–associated anti-DR6 therapies, which can
be tested in laying hens. Taken together, information on the association
of DR6 with the early detection of OVCA and the potential develop-
ment of anti-DR6–based therapies will establish the foundation for
clinical studies. It may thus ultimately lead to the development of an
effective diagnostic test and therapies for OVCA at an early stage.
In conclusion, this study showed that the tissue expression of DR6,
a potential tumor-associated neoangiogenic and immunosuppressive
factor, was significantly higher in hens with early-stage OVCA than
in hens with normal ovaries and increased further as the disease prog-
ressed to late stages. This information will be useful and contribute to
clinical studies to determine the role of DR6 in OVCA development
and progression in humans.
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